Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence

Cancer Gene Therapy

Volumn 7, Issue 3, 2000, Pages 360-372

  Steiner, Mitchell S ^a,b   Zhang, Yu ^a   Farooq, Farees ^a   Lerner, Jody ^a   Wang, Ying ^a   Lu, Yi ^a,b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Genotherapeutics Inc   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Adenovirus; Gene therapy; P16; Prostate cancer; Retinoblastoma; Senescence

Indexed keywords

COMPLEMENTARY DNA; PROTEIN P16; VIRUS VECTOR;

ADENOVIRUS; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL AGING; CONTROLLED STUDY; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5; MUS MUSCULUS; PAPOVAVIRIDAE; ROUS SARCOMA VIRUS;

EID: 0034115639     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700151     Document Type: Article

References (81)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-30.
2. Spitz FR, Nguyen D, Skibber JM, et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 1996;16:3415-3422.
3. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 1995;55:4210-4213.
4. Ko SC, Gotoh A, Thalmann GN, et al. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther. 1996;7:1683-1691.
5. Nielsen LL, Dell J, Maxwell E, et al. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 1997;4:129-138.
6. Xu M, Kumar D, Srinivas S, et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther. 1997;8:177-185.
7. Hamada K, Alemany R, Zhang WW, et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 1996;56:3047-3054.
8. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. 1996;12:1617-1623.
9. Cirielli C, Riccioni T, Yang C, et al. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int J Cancer. 1995;63:673-679.
10. Steiner MS, Lerner J, Greenberger M, et al. Clinical phase I gene therapy trial using BRCA1 retrovirus is safe. J Urol. 1998;159:133. Abstract.
11. Norbury C, Nurse P. Animal cycles and their control. Annu Rev Biochem. 1992;61:441-470.
12. 1 cyclins. Cell. 1993;73:1059-1065.
13. Bates S, Bonetta L, Macallan D, et al. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene. 1994;9:71-79.
14. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
15. Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 1994;54:6353-6358.
16. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 1994;8:23-26.
17. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753-756.
18. Stone S, Dayananth P, Kamb A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res. 1996;56:3199-3202.
19. Hama S, Sadatomo T, Yoshioka H, et al. Transformation of human glioma cell lines with the p16 gene inhibits cell proliferation. Anticancer Res. 1997;17:1933-1938.
20. INK4. Science. 1995;267:249-252.
21. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 1995;375:503-506.
22. Diaz MO, Rubbin C, Harden A, et al. Deletion of interferon genes in acute lymphoblastic leukemia. N Engl J Med. 1990;322:77-82.
23. Fountain JW, Karaviorgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA. 1992;89:10557-10561.
24. James CD, He J, Collins VP, et al. Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group. Cancer Res. 1993;53:3674-3676.
25. Orlow I, Lacombe L, Hannon GJ, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst. 1995;87:1524-1529.
26. Caldas C, Hahn SA, De Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8:27-32.
27. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
28. Mori T, Miura K, Aoki T, et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 1994;54: 3396-3397.
29. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8:15-21.
30. Hatta Y, Hirama T, Miller CW, et al. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood. 1995;85:2699-2704.
31. Takeuchi S, Bartram CR, Seriu T, et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/ INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood. 1995;86: 755-760.
32. Xiao S, Li D, Vijg J, et al. Codeletions of p15 and p16 in primary malignant mesothelioma. Oncogene. 1995;11:511-515.
33. Washimi O, Nagatake M, Osada H, et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res. 1995; 55:514-517.
34. Xiao S, Li D, Corson JM, et al. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res. 1995;55:2968-2971.
35. Li YJ, Hoang-Xuan K, Delattre JY, et al. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene. 1995;11:597-600.
36. INK4, methylthio-adenosine phosphorylase, and the α- and β-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res. 1996;56:1083-1090.
37. Cairns P, Polascik TJ, Eby Y, Sidransky D. High frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet. 1995;11:210-212.
38. ink4A transcript. Cancer Res. 1995;55:2995-2997.
39. INK4BI. Cancer Res. 1996;56:722-727.
40. Jarrard DF, Bova GS, Ewing CM, et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/ MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer. 1997;19:90-96.
41. Itoh N, Kakehi Y, Akao T, et al. Concomitant presence of p16/cyclin-dependent kinase 4 and cyclin D/cyclin-dependent kinase 4 complex in LNCaP prostatic cancer cell line. Jpn J Cancer Res. 1997;88:229-233.
42. Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16:1197-1206.
43. Sambrook J, Fritsch E, Maniatis T. Northern blot hybridization. In: Sambrook J, Fritsch E, Maniatis T, eds. Molecular Cloning. Plainview, NY: Cold Spring Harbor Laboratory Press; 1989:7.43-7.50.
44. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology. 1988;163: 614-617.
45. Kingston RE. Introduction of DNA into mammalian cells. In: Ausubel FM, Brent R, Kingston RE, et al, eds. Current Protocols in Molecular Biology. 2nd ed. New York: John Wiley & Sons; 1993:9.1.4-9.1.9.
46. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, ed. Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols. Clifton, NJ: The Human Press Inc.; 1991:109-128.
47. Lu Y, Whitaker L, Li X, et al. Coexpression of galectin-1 and its complementary glycoconjugates laminin and lysosome-associated membrane proteins in murine PCC4.aza1R embryonal carcinoma cells induced to differentiation by butyrate. Mol Cell Differ. 1995;3:175-191.
48. Eastham JA, Chen S-H, Sehgal I, et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther. 1996; 7:515-523.
49. Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res. 1997;57: 4511-4516.
50. INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer. 1997;74:255-259.
51. INK4A as a human tumor suppressor. Biochim Biophys Acta. 1996;1242:165-169.
52. INK4 in human cancer. Proc Natl Acad Sci USA. 1994;91:11045-11049.
53. Liu Q, Neuhausen S, McClure M, et al. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene. 1995;10:1061-1067.
54. INK4A) somatic and germline mutations. Hum Mutat. 1995;7:294-303.
55. WAF1/CIP1 in human breast cancer. Int J Cancer. 1995;63:584-591.
56. Dutrillaux B, Gerbault-Sereau M, Zafrabi B. Characterization of chromosomal abnormalities in human breast cancer: a comparison of 30 paradiploid cases with few chromosomal changes. Cancer Genet Cytogenet. 1990;49: 203-217.
57. Sato T, Tanigami A, Yamakawa K, et al. Allelotype ofbreast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res. 1990;50: 7184-7189.
58. INK4A expression in human breast cancer. Am J Pathol. 1996;149:15-20.
59. Reed JA, Loganzo F, Shea CR, et al. Loss of expression of the p15/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995;55:2713-2718.
60. INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst. 1995;87:1870-1875.
61. INK4 expression in nonsmall cell lung carcinoma. Cancer. 1997;80:389-395.
62. Gaddipati JP, McLeod DG, Sesterhenn IA, et al. Mutations of the p16 gene product are rare in prostate cancer. Prostate. 1997;30:188-194.
63. Isaacs WB. Molecular genetics of prostate cancer. Cancer Surv. 1995;25:357-379.
64. Arap W, Nishikawa R, Furnari FB, et al. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res. 1995;55:1351-1354.
65. CDKN4) in human prostate cancers. J Urol. 1997;158:636-641.
66. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med. 1997;3:313-319.
67. Fueyo J, Gomez-Manzano C, Yung WK, et al. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene. 1996;12:103-110.
68. INK4. Cancer Gene Ther. 1996;3:357-364.
69. INKa/CDK2 gene in leukaemic cell lines inhibits cell proliferation. Br J Haematol. 1996;95:291-298.
70. Steiner MS, Wang Y, Zhang Y, et al. p16/MTS1/INK4A suppresses prostate cancer by both pRb-dependent and -independent pathways. Oncongene. In Press.
71. INK4A expression in resected non-small cell lung tumors. Cancer Res. 1996;56:3415-3420.
72. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med. 1997; 3:5-20.
73. INK4 as upstream regulators of Myc. Oncogene. 1997;15:179-192.
74. Hetts SW. To die or not to die: an overview of apoptosis and its role in disease. JAMA. 1998;279:300-307.
75. CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol. 1996;16:859-867.
76. Serrano M, Lee H, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85:27-37.
77. INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene. 1996;13:561-568.
78. Reznikoff CA, Yeager TR, Belair CD, et al. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res. 1996;56:2886-2890.
79. cip1 in spontaneously immortalized human fibroblasts. Cell Growth Differ. 1998;9:139-146.
80. INK4A. Oncogene. 1997;15:505-514.
81. Matsumura Y, Yamagishi N, Miyakoshi J, et al. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. Cancer Lett. 1997;115: 91-96.